Legal & General Group Plc raised its position in shares of Haemonetics Corporation (NYSE:HAE) by 5.1% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 104,958 shares of the medical instruments supplier’s stock after purchasing an additional 5,065 shares during the quarter. Legal & General Group Plc owned 0.20% of Haemonetics worth $4,703,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in Haemonetics by 1.0% during the 2nd quarter. Vanguard Group Inc. now owns 4,743,044 shares of the medical instruments supplier’s stock valued at $187,303,000 after purchasing an additional 48,719 shares in the last quarter. Wells Fargo & Company MN increased its stake in Haemonetics by 9.3% during the 2nd quarter. Wells Fargo & Company MN now owns 2,788,122 shares of the medical instruments supplier’s stock valued at $110,104,000 after purchasing an additional 238,294 shares in the last quarter. Victory Capital Management Inc. increased its stake in Haemonetics by 18.7% during the 3rd quarter. Victory Capital Management Inc. now owns 2,414,526 shares of the medical instruments supplier’s stock valued at $108,340,000 after purchasing an additional 381,012 shares in the last quarter. HealthCor Management L.P. increased its stake in Haemonetics by 15.9% during the 2nd quarter. HealthCor Management L.P. now owns 1,854,872 shares of the medical instruments supplier’s stock valued at $73,249,000 after purchasing an additional 254,872 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Haemonetics by 2.4% in the second quarter. Dimensional Fund Advisors LP now owns 1,739,734 shares of the medical instruments supplier’s stock worth $68,702,000 after acquiring an additional 40,381 shares during the period.
In other news, Director Susan Bartlett Foote sold 16,926 shares of the business’s stock in a transaction on Friday, November 10th. The shares were sold at an average price of $54.19, for a total value of $917,219.94. Following the transaction, the director now owns 27,313 shares of the company’s stock, valued at $1,480,091.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CAO Dan Goldstein sold 4,691 shares of the business’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $54.93, for a total transaction of $257,676.63. Following the completion of the transaction, the chief accounting officer now directly owns 3,747 shares in the company, valued at approximately $205,822.71. The disclosure for this sale can be found here. Insiders have sold 54,486 shares of company stock worth $3,050,827 in the last ninety days. Insiders own 1.20% of the company’s stock.
Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.07. Haemonetics had a net margin of 0.50% and a return on equity of 11.16%. The business had revenue of $225.40 million for the quarter, compared to the consensus estimate of $219.12 million. During the same quarter in the previous year, the firm earned $0.38 earnings per share. The company’s revenue for the quarter was up 2.3% on a year-over-year basis. analysts predict that Haemonetics Corporation will post 1.7 EPS for the current fiscal year.
A number of brokerages have recently commented on HAE. Zacks Investment Research lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Monday, November 20th. Morgan Stanley reiterated an “equal weight” rating and issued a $43.00 price target (up from $38.00) on shares of Haemonetics in a research note on Friday, October 6th. Jefferies Group lifted their price target on shares of Haemonetics from $18.00 to $75.00 and gave the stock a “buy” rating in a research note on Monday. Raymond James Financial upgraded shares of Haemonetics from an “underperform” rating to a “market perform” rating in a research note on Tuesday, January 2nd. Finally, Craig Hallum restated a “hold” rating and set a $50.00 target price (up from $40.00) on shares of Haemonetics in a research report on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $58.83.
TRADEMARK VIOLATION NOTICE: “Legal & General Group Plc Acquires 5,065 Shares of Haemonetics Corporation (HAE)” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://stocknewstimes.com/2018/01/11/legal-general-group-plc-raises-position-in-haemonetics-corporation-hae.html.
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.